Related Experiment Videos
Cardiac hypertrophy and antihypertensive therapy
Cardiovascular Research
|September 1, 1977
Summary
Minoxidil controlled blood pressure in hypertensive rats but increased cardiac hypertrophy markers. Propranolol and methyldopa showed different effects on blood pressure and cardiac hypertrophy, suggesting blood pressure control isn't the only factor.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Biochemistry
Background:
- Cardiac hypertrophy is a significant concern in hypertension.
- Understanding the biochemical and humoral factors influencing cardiac hypertrophy is crucial for effective treatment.
Purpose of the Study:
- To investigate the effects of minoxidil and propranolol on biochemical and humoral factors in spontaneously hypertensive rats (SHR).
- To determine the role of blood pressure control versus other factors in reversing cardiac hypertrophy.
Main Methods:
- Measurements of myocardial DNA, RNA, hydroxyproline, plasma renin activity (PRA), and kidney renin activity (KRA) in SHR and normotensive rats (NR).
- Administration of minoxidil or propranolol to assess their impact on blood pressure, ventricular weight, and biochemical markers.
- Comparison with methyldopa treatment for blood pressure control and hypertrophy reversal.
Main Results:
- Minoxidil effectively lowered blood pressure in SHR but increased PRA, KRA, ventricular weight, and myocardial DNA, RNA, and hydroxyproline.
- Propranolol did not significantly reduce blood pressure in SHR but lowered PRA and KRA, with a slight reduction in ventricular weight.
- Methyldopa controlled blood pressure, lowered PRA, and reversed cardiac hypertrophy.
Conclusions:
- While blood pressure control is important for reversing cardiac hypertrophy, it may not be the sole determining factor.
- Different antihypertensive drugs have varying effects on cardiac hypertrophy, mediated by distinct biochemical and humoral pathways.